Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported ...

Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...

On April 15, Kim Bolton, President & Portfolio Manager at Black Swan Dexteritas, appeared on BNN Bloomberg to share his ...

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...

On Thursday, H.C. Wainwright lifted its price target on shares of Cingulate (NASDAQ: CING) to $20.00, a significant increase from the previous target of $8.00. The firm has maintained a Buy rating on ...

Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned ...

Cingulate (CING) has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5M. The transaction was structured as a non-convertible, unsecured promissory ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate will use the money ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Kansas City, Kansas ...

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...